A new research paper, which has been explored in an article on the Bioengineering website, proposes a research construct for further investigation consisting of a distinct subtype of lupus patients whose illness shares characteristic with ME/CFS. The original paper was published in the Journal of Translational Medicine on September 25th, and Dr Charles Shepherd provides comment on this latest development below.
Extracts from Bioengineer article:
“…many patients with long-standing lupus continue to suffer from profound fatigue, cognitive fog, unrefreshing sleep, and poor exercise tolerance even when their inflammatory disease activity is well controlled or in full remission. A new commentary published in the Journal of Translational Medicine argues that this persistent symptom burden may not be a residual echo of inflammation at all, but the signature of a biologically distinct subgroup of patients whose illness shares striking mechanistic features with myalgic encephalomyelitis/chronic fatigue syndrome, commonly abbreviated as ME/CFS.
The commentary, authored by Lotte Habermann-Horstmeier of the Villingen Institute of Public Health in Germany, does not present new experimental data. Instead, it offers something arguably more valuable at this stage of the field: a structured, testable framework. Drawing on a targeted synthesis of literature from PubMed and Web of Science, the author sorts evidence into three categories—direct SLE findings, findings from ME/CFS research, and cross-condition mechanistic inference—and insists that these be kept rigorously separate. The result is a hypothesis-generating proposal for an SLE–ME/CFS research phenotype, a defined subgroup of lupus patients whose symptoms persist for at least six months, worsen after exertion, and include unrefreshing sleep, cognitive symptoms, or orthostatic intolerance, once alternative explanations and comorbidities have been systematically excluded.
…Methodological caution runs throughout the proposal. The commentary is explicitly a theoretical, non-systematic synthesis, prioritizing human studies, systematic reviews, meta-analyses, and translational work, and it stops short of defining a new diagnostic entity or a fixed disease trajectory. The proposed phenotype is framed as a research construct—a way to stratify patients for prospective longitudinal studies—rather than a clinical diagnosis. This distinction is important for lupus care, where symptoms such as fatigue and cognitive difficulty can also arise from hypothyroidism, anemia, sleep apnea, depression, medication side effects, or active disease that standard measures miss. The framework therefore requires structured exclusion or assessment of alternative explanations before a patient is classified within the subgroup, mirroring the case-definition discipline developed in ME/CFS research.”
MEA Comment:
Good to see this research taking place because lupus (SLE/systemic lupus erythematosus) is an inflammatory and immunological condition that has a number of symptoms – fatigue, joint and muscle pain, cognitive dysfunction – that overlap with ME/CFS .
So lupus can sometimes be misdiagnosed as ME/CFS and it should form part of the differential diagnosis of ME/CFS – as I explain in more detail in the Diagnosis section of the ME Association ME/CFS/PVFS Clinical & Research Guide on page 58. This is especially so in people who have joint pain or antinuclear antibodies if immunological blood testing has been carried out.
In addition, as the researchers point out, some people with lupus appear to have an ME/CFS component to their illness and this is something that needs to be explored as it could provide useful information that will help both groups of people.
Dr Charles Shepherd,
Trustee and Hon. Medical Adviser to the ME Association,
Member of the 2018-2021 NICE guideline on ME/CFS committee,
Member of the 2002 Chief Medical Officer's Working Group on ME/CFS
